The below clickable headlines link directly to outside media outlets, which featured UNC School of Medicine faculty starting Friday, October 17, 2025.
New diabetes pill cuts risk of heart attack and stroke – Dr. John Buse (knowridge)
Postpartum Depression: Better Remedies, and Now a Predictive Blood Test – Dr. Samantha Meltzer-Brody (Medscape)
A Blood Test Can Now Predict a Mother’s Risk of Postpartum Depression – Dr. Samantha Meltzer-Brody (Smithsonian Magazine)
Funnel cakes and belly aches: How to survive fair food season – Shelly Wegman (WRAL)
Study offers clinical evidence on how food delivery models can reduce food insecurity and improve health outcomes – Dr. Seth A. Berkowitz (Tech and Science Post)
Just four days of junk food can wreck your memory, study finds – Dr. Juan Song (MSN Ireland)
Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NPM1/KMT2A-Altered AML – Dr. Joshua Zeidner (OncLive)
2 UNC Health physicians elected to National Academy of Medicine – Dr. Cristy Page (CBS17)
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes – Dr. John B. Buse (The American Journal of Managed Care)
Doctors Without Walls Updates Donors on Street Medicine Work – Dr. Crister Brady (Santa Barbara Independent)
Menopause Expert Available to Discuss Upcoming Changes to Hormone Therapy ‘Black Box’ Warning – Dr. Genevieve Neal-Perry (Newswise)
Reversing peanut advice prevented tens of thousands of allergy cases, researchers say – Dr. Corinne Keet (NPR)
Just 4 Days of Fast Food Could Impair Your Memory, Scientists Say – Dr. Juan Song (Food & Wine Magazine)
Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill – Dr. John Buse (CNBC)
An important development for Novo Nordisk’s GLP-1 pill – Dr. John Buse (INDIA DAILY MAIL)
Dr. Robert Ferris & Dr. Samantha Meltzer-Brody UNC Health chief of oncology clinical services & Executive Dean of the UNC School of Medicine – Dr. Robert Ferris & Dr. Samantha Meltzer-Brody (WPTF)
Bias can lead to better therapies – Dr. Zoe McElligott (Sanford Burnham Prebys Medical Discovery Institute)
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study – Dr. Genevieve Neal-Perry (Associated Press)
Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients – Dr. John B. Buse (TCTMD)